相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer A Randomized Clinical Trial
Veronica Mariotti et al.
JAMA ONCOLOGY (2021)
Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression
Zachary P. McKay et al.
JOURNAL OF IMMUNOLOGY (2021)
IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization
Souvik Dey et al.
CANCER IMMUNOLOGY RESEARCH (2021)
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
Vienna Ludovini et al.
GENES (2021)
The emerging roles of IDO2 in cancer and its potential as a therapeutic target
Pengcheng Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
Na Niu et al.
HUMAN PATHOLOGY (2021)
Current Challenges for IDO2 as Target in Cancer Immunotherapy
Giada Mondanelli et al.
FRONTIERS IN IMMUNOLOGY (2021)
IDO1-Targeted Therapy Does Not Control Disease Development in the Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
Selcen Ozturk et al.
CANCERS (2021)
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review
Daniel J. Lin et al.
CLINICAL OTOLARYNGOLOGY (2021)
The IFN-γ-IDO1-kynureine pathway-induced autophagy in cervical cancer cell promotes phagocytosis of macrophage
Shao-Liang Yang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Human monocytic myeloid-derived suppressor cells impair B-cell phenotype and function in vitro
Jennifer Jaufmann et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
The therapeutic potential of targeting tryptophan catabolism in cancer
Christiane A. Opitz et al.
BRITISH JOURNAL OF CANCER (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1
Sean Hacking et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation
Giada Mondanelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Tumor intrinsic and extrinsic immune functions of CD155
Jake. S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2020)
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs
Chiara Porta et al.
CANCER RESEARCH (2020)
Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
Baosheng Chen et al.
CANCER IMMUNOLOGY RESEARCH (2020)
The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture
S. Di Blasio et al.
NATURE COMMUNICATIONS (2020)
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
Kristiina Karihtala et al.
CANCERS (2020)
CRISPR screen in regulatory T cells reveals modulators of Foxp3
Jessica T. Cortez et al.
NATURE (2020)
Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer
Lijuan Wei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai et al.
FRONTIERS IN IMMUNOLOGY (2020)
IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma
Ruidi Jiao et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Min-Hee Oh et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Ahmed Sadik et al.
CELL (2020)
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Luis Felipe Campesato et al.
NATURE COMMUNICATIONS (2020)
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model
Astero Klampatsa et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective
Xi Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma
John F. Tierney et al.
JOURNAL OF SURGICAL RESEARCH (2020)
Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients
Kashif Asghar et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Carmen Salvador-Coloma et al.
EUROPEAN JOURNAL OF CANCER (2020)
Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells
Hiroshi Takei et al.
ARTHRITIS RESEARCH & THERAPY (2020)
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy
Zachary Chinn et al.
HISTOPATHOLOGY (2019)
Targeting natural killer cells in solid tumors
Guillaume Habif et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
IDO1 Inhibition Overcomes Radiation-Induced Rebound Immune Suppression by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Ailin Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation
R. Jitschin et al.
LEUKEMIA (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Innate lymphoid cells as regulators of the tumor microenvironment
Sonia Tugues et al.
SEMINARS IN IMMUNOLOGY (2019)
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Gaurav Nayyar et al.
FRONTIERS IN ONCOLOGY (2019)
CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production
Junxing Qu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Maisa C. Takenaka et al.
NATURE NEUROSCIENCE (2019)
PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+T regulatory cells
Thiago Vidotto et al.
PROSTATE (2019)
Tumor Microenvironment as A Game Changer in Cancer Radiotherapy
Magdalena Jarosz-Biej et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Zhen Xiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Indoleamine 2,3-Dioxygenase Activation by Interferon Gamma in Vascular Endothelial Rat Cells Requires Noncanonical NF-κB Signaling
Yingzi Liang et al.
TRANSPLANTATION PROCEEDINGS (2019)
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways
Arum Park et al.
JOURNAL OF CLINICAL MEDICINE (2019)
MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway
Lin Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Analysis of the control mechanism of lung cancer of caspase recruitment domain-containing protein 9 and myeloid-derived suppressor cell in Lewis lung cancer mice model
Xiaowei Wu et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2019)
Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells
Marco Gargaro et al.
FRONTIERS IN IMMUNOLOGY (2019)
miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer
Qiong Lou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1
Yuan Tian et al.
AGING-US (2019)
Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment
Amy J. Petty et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
Rami S. Komrokji et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
M. Lisa Zhang et al.
MODERN PATHOLOGY (2019)
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets
Sergej Tomic et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers
Guanglin Cui et al.
PATHOLOGY & ONCOLOGY RESEARCH (2018)
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
Sarah Yentz et al.
BIODRUGS (2018)
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Zachary J. Brown et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
Ailin Li et al.
CANCER LETTERS (2018)
High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
Andreas Seeber et al.
CANCER SCIENCE (2018)
Discovery of a polysaccharide from the fruiting bodies of Lepista sordida as potent inhibitors of indoleamine 2, 3-dioxygenase (IDO) in HepG2 cells via blocking of STAT1-mediated JAK-PKC-δ signaling pathways
Qiang Luo et al.
CARBOHYDRATE POLYMERS (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Paracrine Wnt5a-beta-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization
Fei Zhao et al.
IMMUNITY (2018)
STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells
Yuying Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Qian Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
Lijuan Wei et al.
FRONTIERS IN IMMUNOLOGY (2018)
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Characterization of the Selective lndoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Bruno Gomes et al.
MOLECULAR CANCER THERAPEUTICS (2018)
IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a
Jiahui Zhang et al.
MOLECULAR IMMUNOLOGY (2018)
被撤回的出版物: TGF-β secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis (Retracted article. See JAN, 2023)
Danhua Zhang et al.
CELL CYCLE (2018)
The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma
Yuko Miyasato et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2018)
Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1
Sonia Moretti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Tumor-associated macrophages: implications in cancer immunotherapy
Amy J. Petty et al.
IMMUNOTHERAPY (2017)
Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition
Jinfeng Pan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis
Xiao-lei Gao et al.
ONCOTARGETS AND THERAPY (2017)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu et al.
NATURE COMMUNICATIONS (2017)
STATs in NK-Cells: The Good, the Bad, and the Ugly
Dagmar Gotthardt et al.
FRONTIERS IN IMMUNOLOGY (2017)
Interlekukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Supressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer
Mengmeng Jiang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas
Vidyalakshmi Chandramohan et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells
Kristian M. Hargadon et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
Indoleamine 2,3-dioxygenase downregulates T-cell receptor complex ζ-chain and c-Myc, and reduces proliferation, lactate dehydrogenase levels and mitochondrial glutaminase in human T-cells
Theodoros Eleftheriadis et al.
MOLECULAR MEDICINE REPORTS (2016)
Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia
Iman Mansour et al.
HEMATOLOGY (2016)
Tolerogenic Phenotype of IFN-γ-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop
Qingsheng Li et al.
JOURNAL OF IMMUNOLOGY (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity
Damya Laoui et al.
NATURE COMMUNICATIONS (2016)
Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation
J-t Cheng et al.
ONCOGENESIS (2016)
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Arpita Mondal et al.
EBIOMEDICINE (2016)
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
Rikke B. Holmgaard et al.
EBIOMEDICINE (2016)
Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells
Theodoros Eleftheriadis et al.
IMMUNOLOGY (2015)
TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells
Hemn Mohammadpour et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner
A. Nouel et al.
JOURNAL OF AUTOIMMUNITY (2015)
Regulatory Rebound in IL-12-Treated Tumors Is Driven by Uncommitted Peripheral Regulatory T Cells
Qingsheng Li et al.
JOURNAL OF IMMUNOLOGY (2015)
PI3k and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization
Marwan Mounayar et al.
STEM CELLS (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
Alisha Holtzhausen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
Madhav D. Sharma et al.
SCIENCE ADVANCES (2015)
Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma
Kyung-Ju Kim et al.
PLOS ONE (2015)
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Georgios Pantouris et al.
AMINO ACIDS (2014)
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Regina Jitschin et al.
BLOOD (2014)
Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction
Yun-Peng Peng et al.
BMC CANCER (2014)
Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Yanmei Han et al.
HEPATOLOGY (2014)
Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer
Jinpu Yu et al.
JOURNAL OF IMMUNOLOGY (2014)
Epstein-Barr Virus Infection Induces Indoleamine 2,3-Dioxygenase Expression in Human Monocyte-Derived Macrophages through p38/Mitogen-Activated Protein Kinase and NF-κB Pathways: Impairment in T Cell Functions
Wan-li Liu et al.
JOURNAL OF VIROLOGY (2014)
Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Yumeng Mao et al.
CANCER RESEARCH (2013)
Canonical and Noncanonical Wnt Proteins Program Dendritic Cell Responses for Tolerance
Cecilia Oderup et al.
JOURNAL OF IMMUNOLOGY (2013)
Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
Maria Grazia Iachininoto et al.
MOLECULES (2013)
Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
Kentaro Mitsuka et al.
NEUROSURGERY (2013)
Shaping of NK Cell Responses by the Tumor Microenvironment
Ana Stojanovic et al.
CANCER MICROENVIRONMENT (2013)
Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
Gabriella Pietra et al.
CANCER RESEARCH (2012)
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
Uciane K. Scarlett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Dichotomous Effects of IFN-γ on Dendritic Cell Function Determine the Extent of IL-12-Driven Antitumor T Cell Immunity
Jamie L. Harden et al.
JOURNAL OF IMMUNOLOGY (2011)
Wnt5a Skews Dendritic Cell Differentiation to an Unconventional Phenotype with Tolerogenic Features
Jaris Valencia et al.
JOURNAL OF IMMUNOLOGY (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells
Antonio Curti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
Transmission of donor melanoma by organ transplantation
Dirk C. Strauss et al.
LANCET ONCOLOGY (2010)
Activation of β-Catenin in Dendritic Cells Regulates Immunity Versus Tolerance in the Intestine
Santhakumar Manicassamy et al.
SCIENCE (2010)
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Feng Qian et al.
CANCER RESEARCH (2009)
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
Jonathan R. Brody et al.
CELL CYCLE (2009)
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells
Moses K. Donkor et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase Cδ-STAT1 Signaling Pathway in Interferon-γ-stimulated Murine Dendritic Cells
Young-Il Jeong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Hemoglobin Induces the Expression of Indoleamine 2,3-Dioxygenase in Dendritic Cells Through the Activation of PI3K, PKC, and NF-κB and the Generation of Reactive Oxygen Species
Nanako Ogasawara et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction
Jeng-Wei Tjiu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Christoph F. A. Vogel et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Mononuclear myeloid-derived suppressor cells express RAE-1 and activate natural killer cells
Norman Nausch et al.
BLOOD (2008)
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
Wei Chen et al.
JOURNAL OF IMMUNOLOGY (2008)
Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4(+)CD25(+) regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model
Min-Jung Park et al.
ARTHRITIS RESEARCH & THERAPY (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
IDO and regulatory T cells:: a role for reverse signalling and non-canonical NF-κB activation
Paolo Puccetti et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Noncanonical NF-κB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation
Sander W. Tas et al.
BLOOD (2007)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer
Takafumi Nakamura et al.
CANCER SCIENCE (2007)
Altered activation of AKT is required for the suppressive function of human CD4+ CD25+ T regulatory cells
Natasha K. Crellin et al.
BLOOD (2007)
The pancreatic stellate cell: a star on the rise in pancreatic diseases
M. Bishr Omary et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
NF-κB activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-γ and tumor necrosis factor-α
Cory M. Robinson et al.
CYTOKINE (2006)
Essential role of IκB kinase α in thymic organogenesis required for the establishment of self-tolerance
Dan Kinoshita et al.
JOURNAL OF IMMUNOLOGY (2006)
The transmission of donor-derived malignant melanoma to a renal allograft recipient
C. A. Milton et al.
CLINICAL TRANSPLANTATION (2006)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
D Braun et al.
BLOOD (2005)
The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase
CM Robinson et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
C Orabona et al.
NATURE IMMUNOLOGY (2004)
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase
AL Mellor et al.
INTERNATIONAL IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α
CM Robinson et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2003)
Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery
RM MacKie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CTLA-4-Ig regulates tryptophan catabolism in vivo
U Grohmann et al.
NATURE IMMUNOLOGY (2002)
The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways
E Dejardin et al.
IMMUNITY (2002)
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection
M Friberg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells
F Fallarino et al.
INTERNATIONAL IMMUNOLOGY (2002)
Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway
U Senftleben et al.
SCIENCE (2001)
Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-γ-activated human macrophages:: Posttranslational regulation by pyrrolidine dithiocarbamate
SR Thomas et al.
JOURNAL OF IMMUNOLOGY (2001)
IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-γ production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21
U Kalina et al.
JOURNAL OF IMMUNOLOGY (2000)
Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-γ
MX Du et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2000)
分享论文
